CAMP4 Therapeutics (NASDAQ:CAMP) Posts Earnings Results, Misses Estimates By $0.17 EPS

CAMP4 Therapeutics (NASDAQ:CAMP) posted its quarterly earnings data on Thursday. The Wireless communications provider reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.17), FiscalAI reports. The company had revenue of $1.90 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.

CAMP4 Therapeutics Stock Down 0.5%

CAMP traded down $0.02 during trading on Thursday, hitting $3.72. 191,098 shares of the company traded hands, compared to its average volume of 202,317. The firm has a market cap of $233.43 million, a P/E ratio of -1.60 and a beta of 0.28. CAMP4 Therapeutics has a one year low of $2.90 and a one year high of $7.75. The stock’s fifty day moving average is $3.84 and its 200 day moving average is $4.20.

Insider Activity at CAMP4 Therapeutics

In other news, CFO Kelly Gold acquired 10,000 shares of CAMP4 Therapeutics stock in a transaction on Monday, August 31st. The stock was acquired at an average cost of $3.96 per share, with a total value of $39,600.00. Following the completion of the acquisition, the chief financial officer owned 10,000 shares in the company, valued at approximately $39,600. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Andrew J. Schwab sold 400,000 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the sale, the director directly owned 2,033,270 shares of the company’s stock, valued at $8,214,410.80. This represents a 16.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 593,613 shares of company stock valued at $2,504,037. 21.69% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC purchased a new stake in CAMP4 Therapeutics in the 2nd quarter worth about $27,581,000. 5AM Venture Management LLC bought a new stake in CAMP4 Therapeutics in the 2nd quarter valued at about $25,647,928. Trails Edge Capital Partners LP bought a new stake in CAMP4 Therapeutics in the 2nd quarter valued at about $8,446,935. BlackRock Inc. purchased a new stake in CAMP4 Therapeutics during the second quarter valued at about $7,185,000. Finally, SummitTX Capital L.P. purchased a new stake in CAMP4 Therapeutics during the first quarter valued at about $1,497,000.

Analyst Upgrades and Downgrades

CAMP has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Tuesday, September 29th. Raymond James Financial started coverage on CAMP4 Therapeutics in a research report on Friday, October 23rd. They set a “strong-buy” rating and a $10.00 target price on the stock. UBS Group set a $15.00 target price on CAMP4 Therapeutics in a report on Friday, August 14th. Chardan Capital dropped their price target on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, September 29th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, CAMP4 Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $10.44.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.